Search

Your search keyword '"Lea Bruhn"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Lea Bruhn" Remove constraint Author: "Lea Bruhn"
27 results on '"Lea Bruhn"'

Search Results

1. Discordance Between Glucose Levels Measured in Interstitial Fluid vs in Venous Plasma After Oral Glucose Administration: A Post-Hoc Analysis From the Randomised Controlled PRE-D Trial

2. Effect of exercise training on skeletal muscle protein expression in relation to insulin sensitivity: Per‐protocol analysis of a randomized controlled trial (GO‐ACTIWE)

3. Exercise-induced molecular mechanisms promoting glycogen supercompensation in human skeletal muscle

4. Predicting the HbA1c level following glucose-lowering interventions in individuals with HbA1c-defined prediabetes: a post-hoc analysis from the randomized controlled PRE-D trial

5. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

6. Physiological factors contributing to HbA1c in the normal and pre-diabetic range: a cross-sectional analysis

7. Timing and Frequency of Daily Energy Intake in Adults with Prediabetes and Overweight or Obesity and Their Associations with Body Fat

8. No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial

9. 844-P: Effects of Dapagliflozin, Metformin, or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial

10. 845-P: Changes in Plasma Levels of Liver Enzymes in Response to Dapagliflozin, Metformin, or Exercise in People with Prediabetes: The PRE-D Trial

11. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

12. Physiological factors contributing to HbA

13. 901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

14. 905-P: Safety, Adherence, and Treatment Satisfaction with Dapagliflozin, Metformin, or Exercise in Individuals with Prediabetes: The Pre-D Trial

15. 131-OR: Effects of Dapagliflozin, Metformin, or Exercise on Glucose Metabolism in Individuals with Prediabetes: The PRE-D Trial

17. Exercise-induced molecular mechanisms promoting glycogen supercompensation in human skeletal muscle

18. 131-OR: Effects of Dapagliflozin, Metformin, or Exercise on Glucose Metabolism in Individuals with Prediabetes: The PRE-D Trial

19. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial)

21. Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function

22. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

23. 901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial.

24. 895-P: Effects of Dapagliflozin, Metformin, or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial.

27. LEAP2 is associated with cardiometabolic markers but is unchanged by antidiabetic treatment in people with prediabetes.

Catalog

Books, media, physical & digital resources